▲
Glenmark expects innovative drugs to drive higher revenue share: CMD Glenn Saldanha
- Glenmark expects innovative drugs to contribute a higher share of revenue as it shifts beyond generics
- Glenmark’s shift beyond generics could reshape its revenue mix for Indian pharma investors